Peter Hollander
Associate professor at Department of Immunology, Genetics and Pathology; Research programme: Cancer Immunotherapy; Research group Rose-Marie Amini
- E-mail:
- peter.hollander@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
More information is available to staff who log in.
Publications
Selection of publications
- Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases (2023)
- Outcome in PCNSL patients and its association with PD-L1+leukocytes in the tumor microenvironment (2022)
- Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue (2022)
- Checkpoint CD47 expression in classical Hodgkin lymphoma (2022)
- Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity (2022)
- LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients (2022)
- PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS (2021)
- Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma (2021)
- Infiltration of CD163-, PD-L1-and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors (2021)
- Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden (2021)
- Patients with autoimmune diseases have an altered activity of the PD-1 pathway and proportions of Epstein-Barr virus infected cells in benign lymphadenopathies (2021)
- Prognostic impact of abdominal lymph node involvement in diffuse large B-cell lymphoma (2020)
- Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome (2020)
- Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma (2020)
Recent publications
- CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression (2024)
- MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 (2024)
- Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases (2023)
- Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma (2023)
- Outcome in PCNSL patients and its association with PD-L1+leukocytes in the tumor microenvironment (2022)
All publications
Articles
- CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression (2024)
- MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 (2024)
- Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases (2023)
- Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma (2023)
- Outcome in PCNSL patients and its association with PD-L1+leukocytes in the tumor microenvironment (2022)
- Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue (2022)
- Checkpoint CD47 expression in classical Hodgkin lymphoma (2022)
- Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity (2022)
- LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients (2022)
- PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS (2021)
- Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma (2021)
- Infiltration of CD163-, PD-L1-and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors (2021)
- Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden (2021)
- Patients with autoimmune diseases have an altered activity of the PD-1 pathway and proportions of Epstein-Barr virus infected cells in benign lymphadenopathies (2021)
- Prognostic impact of abdominal lymph node involvement in diffuse large B-cell lymphoma (2020)
- Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma (2020)
- Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome (2020)
- Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma (2020)
- CD30 expression and survival in posttransplant lymphoproliferative disorders (2020)
- Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients (2019)
- High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms (2019)
- Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma (2018)
- An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome (2018)
- High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome (2017)
- High Expression Of Programmed Cell Death Receptor 1 In The Tumor Microenvironment Is Associated With Inferior Event Free Survival In Classical Hodgkin Lymphoma (2016)
- Prognostic Implications Of An Active, Innate Or Anergic Immune Response In The Hodgkin Lymphoma Tumor Microenvironment (2016)
- Autoimmune and Atopic Disorders and Risk of Classical Hodgkin Lymphoma (2015)
- PD-1 and PD-L1 are upregulated in paired consecutive biopsies with classical Hodgkin lymphoma